lorlatinib
lorlatinib is listed in the FDA National Drug Code directory with 5 NDC codes, marketed under brand name including Lorbrena. Available dosage form: tablet, film coated.
Drug Details
- Generic Name
- lorlatinib
- Brand Names
- Lorbrena
- Application Number
- NDA210868
- Sponsor
- U.S. Pharmaceuticals
- NDC Codes
- 5
- Dosage Forms
- TABLET, FILM COATED
- Routes
- ORAL
- Active Ingredients
- LORLATINIB
Indications and Usage
1 INDICATIONS AND USAGE LORBRENA ® is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. LORBRENA is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. ( 1 , 2.1 )